| Susan L Harris, | |
|
310 6th St Ne, Auburn, WA 98002-4342 | |
| (253) 833-6241 | |
| (253) 833-4113 |
| Full Name | Susan L Harris |
|---|---|
| Gender | Female |
| Speciality | Qualified Audiologist |
| Experience | 30 Years |
| Location | 310 6th St Ne, Auburn, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659542249 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | LD00001154 (Washington) | Primary |
| 237600000X | Audiologist-hearing Aid Fitter | LD00001154 (Washington) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Multicare Health System | 7719899897 | 1704 |
News Archive
The Prostate Cancer Roundtable expressed deep disappointment today as the U.S. Preventive Services Task Force (USPSTF) issued its final recommendation statement against the use of prostate-specific antigen (PSA) testing in the detection of prostate cancer.
Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in "Nature Immunology."
An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.
Yale scientists have systematically plotted the responses of the entire Drosophila (fruit fly) olfactory system, providing the first multi-dimensional map of the range of odorants sensed and the regions of the brain that are stimulated.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
› Verified 2 days ago
| Provider Name | Multicare Health System |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
The Prostate Cancer Roundtable expressed deep disappointment today as the U.S. Preventive Services Task Force (USPSTF) issued its final recommendation statement against the use of prostate-specific antigen (PSA) testing in the detection of prostate cancer.
Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in "Nature Immunology."
An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.
Yale scientists have systematically plotted the responses of the entire Drosophila (fruit fly) olfactory system, providing the first multi-dimensional map of the range of odorants sensed and the regions of the brain that are stimulated.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Susan L Harris, 310 6th St Ne, Auburn, WA 98002-4342 Ph: (253) 833-6241 | Susan L Harris, 310 6th St Ne, Auburn, WA 98002-4342 Ph: (253) 833-6241 |
News Archive
The Prostate Cancer Roundtable expressed deep disappointment today as the U.S. Preventive Services Task Force (USPSTF) issued its final recommendation statement against the use of prostate-specific antigen (PSA) testing in the detection of prostate cancer.
Medical investigators at the Hospital for Special Surgery have identified an important new signaling pathway they believe could be a valuable target for scientists to aim at with future drug therapies that might one day reverse diseases such as systemic lupus erythematosus, according to a recent article published in "Nature Immunology."
An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.
Yale scientists have systematically plotted the responses of the entire Drosophila (fruit fly) olfactory system, providing the first multi-dimensional map of the range of odorants sensed and the regions of the brain that are stimulated.
Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.
› Verified 2 days ago
Trista Elizabeth Smith, AUD, CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 222 2nd St Ne, Auburn, WA 98002 Phone: 253-833-4050 |